Skip to main content

Vipergen ApS
Gammel Kongevej 23A
1^st floor
1610 Copenhagen
Denmark

VAT: DK28851758

info@vipergen.com

Partnering with Vipergen

From straightforward Fee-For-Service to comprehensive joint ventures, we provide flexible partnership structures to align with your project’s distinct needs.

Explore our services

Resources

Latest news

Five More E3 Ubiquitin Ligases Added to Glue Platform

October 19, 2026

Three New Building Block Series Advanced at Vipergen

September 30, 2026

Domainex and Vipergen Partner to Accelerate Hit and Lead Discovery

September 1, 2026

News

October 19, 2026

Five More E3 Ubiquitin Ligases Added to Glue Platform

September 30, 2026

Three New Building Block Series Advanced at Vipergen

September 1, 2026

Domainex and Vipergen Partner to Accelerate Hit and Lead Discovery

August 28, 2026

Vipergen Expands DEL Series with Two Updated Libraries

Vipergen EPO Patent Maintained Following Opposition

New High-Throughput Workflow Streamlines Building Block Conjugation for DNA-Encoded Library Synthesis

Vipergen Expands Glue Screening with Five E3 Ubiquitin Ligases

Vipergen Publishes Review on the Expanding Role of Chemical Libraries in Next-Generation Drug Discovery

October 7, 2025

Vipergen launches new DEL series with Lib100 and updates Series 50 to Lib058

November 11, 2024

SARomics Biostructures and Vipergen collaborate to offer enhanced drug discovery services

Aurigene Pharmaceutical Services Ltd., and Vipergen announce a strategic partnership for offering DNA encoded library (DEL) screening and integrated drug discovery services.

Vipergen and LEO Pharma Partner for DNA Encoded Library (DEL)-Based Drug Discovery for Dermatology Indications

Vipergen Establishes DNA Encoded Library (DEL)-Based Drug Discovery Partnership with Theseus Pharmaceuticals Focused on Targeted Cancer Therapies

December 21, 2021

Vipergen Establishes Research Partnership with Bayer to Discover Novel Compounds for Pharmaceuticals and More Sustainable Crop Protection Solutions

November 23, 2021

Vipergen Establishes Research Partnership with Aligos Therapeutics Focused on DNA Encoded Library (DEL)-Based Drug Discovery for Viral Infections and Liver Diseases

November 15, 2021

Vipergen Establishes Research Partnership with ALK Focused on DNA-Encoded Library (DEL)-Based Drug Discovery for Allergy Immunotherapies

October 21, 2021

BASF and Vipergen accelerate targeted research and development of sustainable crop protection products

September 14, 2021

Vipergen Establishes Research Partnership with PhoreMost Focused on DNA Encoded Library (DEL)-Based Drug Discovery

Vipergen Establishes Partnership with Anavo Therapeutics to Support Phosphatase-Targeted Discovery Programs

Vipergen strengthens leadership by appointing Dr Leif Kongskov Larsen as Director of Biology and promoting Dr Allan Beck Christensen to Director of Screening Technologies

February 17, 2021

Vipergen Publishes First Technology for Screening DNA-Encoded Small-Molecule Libraries (DELs) Inside Living Cells

December 1, 2020

Casma Therapeutics and Vipergen Enter Into Drug Discovery Agreement

November 6, 2020

Commercial release of the first technology for DEL screening inside a living cell

December 20, 2016

Vipergen enters into multi-target drug discovery agreement with Merck

Vipergen enters into multi-target drug discovery agreement with Daiichi Sankyo

Vipergen enters into multi-target drug discovery agreement with Gilead

December 21, 2015

Vipergen enters into multi-target collaboration with Europes largest biopharmaceutical company

December 18, 2015

Vipergen enters into multi-target drug discovery agreement with Amgen